CNBC
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Monday, November 16, 2026
Novo Nordisk's Wegovy injection met its primary endpoint in a trial testing the drug in children under 12 with obesity, lowering body mass index compared to placebo, the company announced. Wegovy is currently approved to treat obesity in children ages 12 and older. The company did not immediately release detailed efficacy or safety data from the trial.
Original reporting:
